A Molecular Profile Monitoring the Advancement of Non-Muscle Invasive Bladder Carcinoma

Category	Detail
Condition	Non-Muscle Invasive Bladder Carcinoma (NMIBC)
Key Mechanisms	Genetic alterations, epithelial-mesenchymal transition (EMT), extracellular matrix remodeling, and abnormal mitotic activity.
Target Population	Patients with NMIBC, particularly those at low, intermediate, and high risk.
Care Setting	Urology clinics and oncology centers.

Bladder cancer is the ninth most common cancer globally, with significant geographic incidence variation.
90% of bladder cancer cases are urothelial carcinoma, with various histological subtypes.
Early diagnosis of NMIBC is crucial for effective treatment and reducing progression to muscle-invasive bladder cancer (MIBC).
BCG therapy is a primary treatment for intermediate- and high-risk NMIBC patients.
NMIBC has a high recurrence rate (50-70%) and progression rate (10-30%).

Cystoscopy and urine cytology are the gold standard for diagnosing bladder cancer.
Imaging methods like ultrasound, CT, and MRI are used to evaluate bladder masses.

Low-risk NMIBC treated with TURBT alone; intermediate/high-risk patients receive adjuvant treatments like BCG.

Molecular profiling and biomarker prediction are emerging tools for monitoring disease progression.

Patients diagnosed with NMIBC, particularly those at varying risk levels.

Adjuvant treatments include Mitomycin C, Epirubicin, and BCG therapy.

Clinical Scorecard: A Molecular Profile Monitoring the Advancement of Non-Muscle Invasive Bladder Carcinoma